This webinar was part of the Virtual Grand Round Series titled: Addressing Unmet Needs in the Treatment of Psychiatric Disorders.

Learning Objectives

At the end of this educational activity, participants should be able to:
  • Identify key diagnostic features of Bipolar Depression.
  • Review the FDA approved pharmacological treatments for Bipolar Depression.
  • Recognize the complications associated with treatments for Bipolar Depression.

Target Audience

Psychiatrists, primary care/family physicians, nurses, allied healthcare professionals.


  • Thomas P. Hackett, MD, Endowed Chair in Psychiatry at MGH,
    Director, Bipolar Clinic and Research Program,
    Associate Director, Depression Clinical and Research Program,
    Director, Training and Education, MGH Research Institute,
    Massachusetts General Hospital,
    Professor of Psychiatry, Harvard Medical School

CME Information

This program is not accredited.

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education. CME credit is not being offered for this activity.

Credit Designation

Even though this event is not accredited, providing information regarding planning, disclosure, and conflict of interest is important to us. Some providers may be able to claim Category 2 CME credit for participating in this activity.


In accord with the guidelines of the Accreditation Council for Continuing Medical Education (ACCME), planners, speakers and anyone who may have an influence on the content of the activity have been asked to disclose any relationship they or their spouse/partner have to companies producing pharmaceuticals, medical equipment, devices, etc. that may be germane to the content of their presentation. Such disclosure is not intended to suggest or condone bias, but provides participants with information that might be of potential importance to their evaluation of a given presentation.


The MGH Academy has implemented a process to resolve potential COIs for this CME activity to help ensure content objectivity, independence, fair balance and ensure that the content is aligned with the interest of the public.

Planner Disclosure

The following planners and/or their spouse/partner have no relevant financial relationship with a commercial interest:

Tristan Gorrindo, MD: Planner

Speaker Disclosure

The following speaker and/or his spouse/partner has reported a relevant financial relationship with a commercial interest:

Andrew Nierenberg, MD

Consultant: Abbott Laboratories, AstraZeneca, Basilea, BrainCells Inc., Brandeis University, Bristol-Myers Squibb, Cephalon, Corcept, Eli Lilly & Co., Forest, Genaissance, GlaxoSmithKline, Innapharma, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Lundbeck, Merck, Novartis, PamLabs, PGx Health, Pfizer, Ridge Diagnostics, Roche, Sepracor, Schering-Plough, Shire, Somerset, Sunovion, Takeda, Targacept, Teva

Stockholder: Applicant Computing, Inc. (MindSite), Brain Cells, Inc., InfoMed (potential share of income)

Research Support: AHRQ, Bristol-Myers Squibb, Cederroth, Cyberonics, Elan, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceuticals, Lichtwer Pharma, Eli Lilly & Co., Mylin Foundation, Wyeth-Ayerst

Honoraria: MGH Psychiatry Academy in the past 3 years (Prior to 3 years ago, honoraria from Bristol-Myers Squibb, Cyberonics, Forest Pharmaceuticals, GlaxoSmithKline, Eli Lilly & Co., Shire, Wyeth-Ayers) No speaker bureaus since 2003

Other Income: Legal case reviews for CRICO, MBL Publisher for past services as Editor-in-chief of CNS Spectrums, Slack Inc. for services as Associate Editor of Psychiatric Annals, Editorial Board, Mind Mood Memory, Belvior Publications

Patents and Copyrights: Copyright joint ownership with MGH for Structured Clinical Interview for MADRS and Clinical Positive Affect Scale

Additional Honoraria: ADURS, American Society for Clinical Psychopharmacology and Zucker Hillside Hospital and Forest and Janssen, Biomedical Development, Boston Center for the Arts, University of Pisa, University of Wisconsin at Madison, University Texas Southwest at Dallas, Health New England and Harold Grinspoon Charitable Foundation and Eli Lilly and AstraZeneca, Brandeis University, International Society for Bipolar Disorder, 2nd East Asian Bipolar Forum, Mid-Atlantic Permantente Research Institute, Up-to-Date


This program was originally developed as an accredited educational activity using support in the form of educational grants from the following companies:

  • Janssen Scientific Affairs, LLC
  • Lilly USA, LLC
  • Sunovion Pharmaceuticals, Inc.
  • Takeda Pharmaceutical International, Inc. and Lundbeck

Hardware/Software Specifications:

This internet-based CME activity is best experienced using Internet Explorer 8+, Mozilla Firefox 3+, Safari 4+. This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Adobe Acrobat, Microsoft PowerPoint, and Windows Media Player.

Optimal System Configuration:

Flash Player: Adobe Flash Player 10.1+
Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+
Operating System: Windows XP+ or Mac OS X 10.4+
Internet Connection: 1 Mbps or higher

Minimum Requirements:

Windows PC: 500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
Macintosh: Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit